Toshiya Osanai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toshiya Osanai has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Kiyohiro Houkin
Affiliation Hokkaido University, Sapporo, Japan
18 shared publicationsKazutoshi Hida
Department of Neurosurgery, Sapporo Azabu Neurosurgical Hospital, Sapporo, Japan
9 shared publications- Miki Fujimura
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
9 shared publications Miki Fujimura
Department of Neurosurgery, Faculty of Medicine, Hokkaido University
8 shared publications- Kikutaro Tokairin
Department of Neurosurgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan
7 shared publications - Taku Sugiyama
Department of Neurosurgery, Hokkaido University Graduate School of Medicine
7 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2718-2732
Cost-utility analysis of surgical revascularization versus conservative management for adult moyamoya disease patients with posterior hemorrhage in Japan
With continuous advances in medical technology and the rapid aging of populations worldwide, healthcare expenditures have increased in Japan [1]. Under these tightening fiscal constraints, health t...
- 12 November 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2718-2732
Open AccessCost-utility analysis of surgical revascularization versus conservative management for adult moyamoya disease patients with posterior hemorrhage in Japan
With continuous advances in medical technology and the rapid aging of populations worldwide, healthcare expenditures have increased in Japan [1]. Under these tightening fiscal constraints, health t...
- Open Access
- 16 September 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 272
Clinical outcome of carotid artery stenting using dual layer stent for radiation induced carotid artery stenosis: Comparative study with single layer stent
- 16 September 2026
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 272
Open AccessClinical outcome of carotid artery stenting using dual layer stent for radiation induced carotid artery stenosis: Comparative study with single layer stent
- Open Access
- 21 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0349756
Cost-effectiveness of stem cell therapy versus standard of care for acute and subacute ischemic stroke
A recent meta-analysis demonstrated the efficacy of stem cell therapy for ischemic stroke; however, its cost-effectiveness has not yet been sufficiently explored. Building on the clinical data from that meta-analysis, we aimed to evaluate the cost-effectiveness of the administration of mesenchymal stem cells for acute and subacute ischemic stroke compared with the standard of care. A cost-utility analysis was performed via simulation by using a Markov model. The participants were patients treated for acute or subacute ischemic stroke in hospitals in Japan. Stem cell therapy plus the standard of care (the stem cell group) was compared with the standard of care alone (the control group). The time horizon was 10 years. The primary outcome was the cost of stem cell therapy when the incremental cost-effectiveness ratio, calculated based on costs and quality-adjusted life years for both groups, was 5 million yen/quality-adjusted life year, the reference value in the cost-effectiveness evaluation in Japan. Efficacy data are obtained from the meta-analysis. Base-case analysis was performed using the most plausible or average values for all input parameters. Scenario and sensitivity analyses were also conducted. In the base case, the stem cell therapy cost when the incremental cost-effectiveness ratio was 5 million yen/quality-adjusted life year was $,3,746 from the public health payer’s perspective and $5,157 from the public healthcare and long-term care payer’s perspective. The scenario and sensitivity analyses supported the cost-effectiveness of stem cell therapy for acute and subacute ischemic stroke. This study provides threshold costs of stem cell therapy at which it becomes cost-effective for acute and subacute ischemic stroke. These results may support rational pricing strategies for stem cell therapy and facilitate its seamless integration into clinical practice.
- 21 May 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (5) , e0349756
Open AccessCost-effectiveness of stem cell therapy versus standard of care for acute and subacute ischemic stroke
A recent meta-analysis demonstrated the efficacy of stem cell therapy for ischemic stroke; however, its cost-effectiveness has not yet been sufficiently explored. Building on the clinical data from that meta-analysis, we aimed to evaluate the cost-effectiveness of the administration of mesenchymal stem cells for acute and subacute ischemic stroke compared with the standard of care. A cost-utility analysis was performed via simulation by using a Markov model. The participants were patients treated for acute or subacute ischemic stroke in hospitals in Japan. Stem cell therapy plus the standard of care (the stem cell group) was compared with the standard of care alone (the control group). The time horizon was 10 years. The primary outcome was the cost of stem cell therapy when the incremental cost-effectiveness ratio, calculated based on costs and quality-adjusted life years for both groups, was 5 million yen/quality-adjusted life year, the reference value in the cost-effectiveness evaluation in Japan. Efficacy data are obtained from the meta-analysis. Base-case analysis was performed using the most plausible or average values for all input parameters. Scenario and sensitivity analyses were also conducted. In the base case, the stem cell therapy cost when the incremental cost-effectiveness ratio was 5 million yen/quality-adjusted life year was $,3,746 from the public health payer’s perspective and $5,157 from the public healthcare and long-term care payer’s perspective. The scenario and sensitivity analyses supported the cost-effectiveness of stem cell therapy for acute and subacute ischemic stroke. This study provides threshold costs of stem cell therapy at which it becomes cost-effective for acute and subacute ischemic stroke. These results may support rational pricing strategies for stem cell therapy and facilitate its seamless integration into clinical practice.
- Open Access
- 2 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0340076
A simulation study of the cost of cerebral vasospasm treatments with clazosentan: A mathematical model using time-driven activity-based costing
In this work, we aimed to assess the impact of clazosentan on clinical labour time costs within Japan’s value-based healthcare system using time-driven activity-based costing. Time-driven activity-based costing was employed to analyse the labour time costs associated with preventing cerebral vasospasm following aneurysmal subarachnoid haemorrhage. Time-driven activity-based costing simplifies cost analysis by utilising time as the primary cost driver. We compared two treatment approaches: conventional therapy with fasudil hydrochloride and postoperative therapy with clazosentan. Scenario and sensitivity analyses were performed to assess the impact of physicians’ costs on the results. The use of clazosentan for the prevention of cerebral vasospasm significantly reduced human resource costs, particularly in cases where symptomatic vasospasm did not occur, yielding savings of approximately 51,343 yen. The greatest cost reductions were observed among nursing staff, with a 30% decrease in the absence of symptomatic vasospasm and a 15% reduction when symptomatic vasospasm was present. The cost reductions for physicians were comparatively smaller, particularly in cases where symptomatic vasospasm occurred. Sensitivity analyses indicated that clazosentan reduced overall costs by approximately 35,000–50,000 yen; however, costs increased in the presence of symptomatic vasospasm. Clazosentan for subarachnoid haemorrhage treatment significantly reduces human resource costs, especially in nursing staff. These findings support the potential of clazosentan for broader clinical use, given its cost-savings and clinical benefits in reducing cerebral vasospasm following aneurysmal subarachnoid haemorrhage.
- 2 January 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (1) , e0340076
Open AccessA simulation study of the cost of cerebral vasospasm treatments with clazosentan: A mathematical model using time-driven activity-based costing
In this work, we aimed to assess the impact of clazosentan on clinical labour time costs within Japan’s value-based healthcare system using time-driven activity-based costing. Time-driven activity-based costing was employed to analyse the labour time costs associated with preventing cerebral vasospasm following aneurysmal subarachnoid haemorrhage. Time-driven activity-based costing simplifies cost analysis by utilising time as the primary cost driver. We compared two treatment approaches: conventional therapy with fasudil hydrochloride and postoperative therapy with clazosentan. Scenario and sensitivity analyses were performed to assess the impact of physicians’ costs on the results. The use of clazosentan for the prevention of cerebral vasospasm significantly reduced human resource costs, particularly in cases where symptomatic vasospasm did not occur, yielding savings of approximately 51,343 yen. The greatest cost reductions were observed among nursing staff, with a 30% decrease in the absence of symptomatic vasospasm and a 15% reduction when symptomatic vasospasm was present. The cost reductions for physicians were comparatively smaller, particularly in cases where symptomatic vasospasm occurred. Sensitivity analyses indicated that clazosentan reduced overall costs by approximately 35,000–50,000 yen; however, costs increased in the presence of symptomatic vasospasm. Clazosentan for subarachnoid haemorrhage treatment significantly reduces human resource costs, especially in nursing staff. These findings support the potential of clazosentan for broader clinical use, given its cost-savings and clinical benefits in reducing cerebral vasospasm following aneurysmal subarachnoid haemorrhage.
- Open Access
- 3 November 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (18)
Coil embolization via donor superficial temporal artery for de novo aneurysm associated with revascularization surgery in a patient with moyamoya disease: illustrative case
BACKGROUND: De novo aneurysm formation at the anastomotic site of superficial temporal artery (STA)–middle cerebral artery (MCA) bypass surgery for moyamoya disease (MMD) is an exceptionally rare but clinically significant complication. Previously reported cases were treated with direct microsurgery, where preservation of established pial synangiosis was a major concern. The authors herein report the first case successfully treated with endovascular coil embolization, achieving complete preservation of pial synangiosis and a favorable clinical outcome. OBSERVATIONS: A 53-year-old man had undergone combined revascularization surgery for MMD 14 years earlier. Although the patient remained asymptomatic, follow-up MR angiography revealed a gradually enlarging de novo aneurysm with daughter sac formation at the anastomotic site. Cerebral angiography demonstrated a narrow-neck saccular aneurysm and a well-developed donor STA, allowing access for endovascular treatment. A microcatheter was advanced into the aneurysm via a distal access catheter placed in the STA, and coil embolization with five coils achieved complete obliteration. The patient recovered uneventfully, and follow-up imaging confirmed the durable occlusion. LESSONS: Endovascular therapy represents a valuable treatment option for de novo aneurysm after STA-MCA anastomosis in MMD, as it completely preserves established collaterals. Careful patient selection and meticulous procedural planning are essential to ensure safety and efficacy. https://thejns.org/doi/10.3171/CASE25666
- 3 November 2025
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 10 (18)
Open AccessCoil embolization via donor superficial temporal artery for de novo aneurysm associated with revascularization surgery in a patient with moyamoya disease: illustrative case
BACKGROUND: De novo aneurysm formation at the anastomotic site of superficial temporal artery (STA)–middle cerebral artery (MCA) bypass surgery for moyamoya disease (MMD) is an exceptionally rare but clinically significant complication. Previously reported cases were treated with direct microsurgery, where preservation of established pial synangiosis was a major concern. The authors herein report the first case successfully treated with endovascular coil embolization, achieving complete preservation of pial synangiosis and a favorable clinical outcome. OBSERVATIONS: A 53-year-old man had undergone combined revascularization surgery for MMD 14 years earlier. Although the patient remained asymptomatic, follow-up MR angiography revealed a gradually enlarging de novo aneurysm with daughter sac formation at the anastomotic site. Cerebral angiography demonstrated a narrow-neck saccular aneurysm and a well-developed donor STA, allowing access for endovascular treatment. A microcatheter was advanced into the aneurysm via a distal access catheter placed in the STA, and coil embolization with five coils achieved complete obliteration. The patient recovered uneventfully, and follow-up imaging confirmed the durable occlusion. LESSONS: Endovascular therapy represents a valuable treatment option for de novo aneurysm after STA-MCA anastomosis in MMD, as it completely preserves established collaterals. Careful patient selection and meticulous procedural planning are essential to ensure safety and efficacy. https://thejns.org/doi/10.3171/CASE25666
- 10 July 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1408-1413
Feasibility and non-inferiority of mobile telementoring for digital subtraction angiography: a single-center observational study
Background Telementoring is an emerging approach in surgical education that offers remote supervision and guidance through digital platforms. This study aimed to evaluate the feasibility and non-inferiority of a mobile-based telementoring system for digital subtraction angiography (DSA) and compare it with traditional face-to-face mentoring. Methods This prospective, single-center observational study included 71 patients who underwent DSA between April 2021 and May 2024. Patients were categorized into control (n=48, face-to-face mentoring) and telementoring (n=23) groups. A mobile telementoring system (JOIN, Allm Inc., Tokyo, Japan), which enabled real-time image sharing and voice communication between the examiner and the remote supervisor, was employed. The primary endpoints were contrast volume, procedural time, and radiation dose, with a non-inferiority margin of 20% applied. Results No significant differences were observed between the two groups in contrast volume (88.3±39.6 mL vs 97.1±36.4 mL, p=0.499), procedural time (44.1±17.7 min vs 50.7±19.0 min, p=0.308), or radiation dose (427.9±262.2 mGy vs 506.6±307.1 mGy, p=0.346). Non-inferiority was confirmed across all primary endpoints. No procedural complications occurred. Qualitative feedback indicated high user satisfaction, with the system facilitating effective remote supervision and decision-making. Conclusions This study demonstrates the feasibility and non-inferiority of a mobile telementoring system for DSA, effectively supporting real-time remote guidance and reducing the need for on-site supervision. Its implementation may enhance access to expert mentoring, particularly in regions with limited specialist availability, contributing to equitable and efficient cerebrovascular care.
- 10 July 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (5) , 1408-1413
Feasibility and non-inferiority of mobile telementoring for digital subtraction angiography: a single-center observational study
Background Telementoring is an emerging approach in surgical education that offers remote supervision and guidance through digital platforms. This study aimed to evaluate the feasibility and non-inferiority of a mobile-based telementoring system for digital subtraction angiography (DSA) and compare it with traditional face-to-face mentoring. Methods This prospective, single-center observational study included 71 patients who underwent DSA between April 2021 and May 2024. Patients were categorized into control (n=48, face-to-face mentoring) and telementoring (n=23) groups. A mobile telementoring system (JOIN, Allm Inc., Tokyo, Japan), which enabled real-time image sharing and voice communication between the examiner and the remote supervisor, was employed. The primary endpoints were contrast volume, procedural time, and radiation dose, with a non-inferiority margin of 20% applied. Results No significant differences were observed between the two groups in contrast volume (88.3±39.6 mL vs 97.1±36.4 mL, p=0.499), procedural time (44.1±17.7 min vs 50.7±19.0 min, p=0.308), or radiation dose (427.9±262.2 mGy vs 506.6±307.1 mGy, p=0.346). Non-inferiority was confirmed across all primary endpoints. No procedural complications occurred. Qualitative feedback indicated high user satisfaction, with the system facilitating effective remote supervision and decision-making. Conclusions This study demonstrates the feasibility and non-inferiority of a mobile telementoring system for DSA, effectively supporting real-time remote guidance and reducing the need for on-site supervision. Its implementation may enhance access to expert mentoring, particularly in regions with limited specialist availability, contributing to equitable and efficient cerebrovascular care.
- Open Access
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Efficacy and safety of stem cell therapy for acute and subacute ischemic stroke: a systematic review and meta-analysis
The efficacy of stem cell therapy for ischemic stroke in terms of functional outcomes remains unclear. We conducted a systematic review and meta-analysis of randomized controlled trials (PROSPERO: CRD42024503763) to assess the efficacy and safety of stem cell therapy for acute/subacute ischemic stroke, focusing on long-term outcomes. Studies of patients undergoing stem cell transplantation within 1 month of stroke onset were included. We searched five databases for publications up to January 17, 2024. Summary data were extracted from published reports. The primary outcome was the modified Rankin Scale (mRS) score. Measures of effect were risk ratios (RRs) with 95% confidence intervals (CIs). A random-effects model was used when I2 was > 25%; otherwise, a fixed-effects model was used. Common serious adverse events were epilepsy, gastrointestinal disorders, and cardiac disorders. The risk of bias was assessed using the Cochrane Risk of Bias tool version 2. In total, 13 trials involving 872 (519 men) patients were included. The 1-year incidence of mRS scores 0–1 was higher in the cell-therapy group (45/195) than that in the control group (23/179; RR = 1.74 [95% CI = 1.09–2.77]; p = 0.020; I2 = 0%). The 90-day incidence of mRS scores 0–2 was also higher (RR = 1.31 [95% CI = 1.01–1.70]; p = 0.044; I2 = 0%). No significant differences were observed in serious adverse events or mortality. Stem cell therapy for acute/subacute ischemic stroke within 1 month of onset is safe and significantly improves long-term functional outcomes, although the mechanisms of action need to be elucidated and treatment protocols standardized to establish stem cell therapy as a standard care option for ischemic stroke.
- 1 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessEfficacy and safety of stem cell therapy for acute and subacute ischemic stroke: a systematic review and meta-analysis
The efficacy of stem cell therapy for ischemic stroke in terms of functional outcomes remains unclear. We conducted a systematic review and meta-analysis of randomized controlled trials (PROSPERO: CRD42024503763) to assess the efficacy and safety of stem cell therapy for acute/subacute ischemic stroke, focusing on long-term outcomes. Studies of patients undergoing stem cell transplantation within 1 month of stroke onset were included. We searched five databases for publications up to January 17, 2024. Summary data were extracted from published reports. The primary outcome was the modified Rankin Scale (mRS) score. Measures of effect were risk ratios (RRs) with 95% confidence intervals (CIs). A random-effects model was used when I2 was > 25%; otherwise, a fixed-effects model was used. Common serious adverse events were epilepsy, gastrointestinal disorders, and cardiac disorders. The risk of bias was assessed using the Cochrane Risk of Bias tool version 2. In total, 13 trials involving 872 (519 men) patients were included. The 1-year incidence of mRS scores 0–1 was higher in the cell-therapy group (45/195) than that in the control group (23/179; RR = 1.74 [95% CI = 1.09–2.77]; p = 0.020; I2 = 0%). The 90-day incidence of mRS scores 0–2 was also higher (RR = 1.31 [95% CI = 1.01–1.70]; p = 0.044; I2 = 0%). No significant differences were observed in serious adverse events or mortality. Stem cell therapy for acute/subacute ischemic stroke within 1 month of onset is safe and significantly improves long-term functional outcomes, although the mechanisms of action need to be elucidated and treatment protocols standardized to establish stem cell therapy as a standard care option for ischemic stroke.
- Open Access
- 1 January 2025
- Published by Japan Stroke Society in Japanese Journal of Stroke
- Vol. 47 (2) , 63-70
Treatment for stroke and medical economics
本論文は,脳卒中と医療経済について概説し,当教室が行ってきた費用対効果分析の研究について紹介するものである.脳卒中は世界的に主要な死因の一つであり,高齢化が進む日本では医療費の削減が重要な課題である.脳卒中の治療には,入院治療,手術,リハビリテーション,予防などがあり,日本ではそれぞれに保険制度や診療報酬の仕組みがある.脳卒中の費用対効果に関する研究は,急性期治療,リハビリテーション,予防などの分野で多く行われており,様々な介入の有効性や経済的影響が評価されている.当教室では,北海道における脳卒中の医療サービスの費用対効果を分析し,医療資源の有効活用に寄与することを目指している.
- 1 January 2025
- Published by Japan Stroke Society in Japanese Journal of Stroke
- Vol. 47 (2) , 63-70
Open AccessTreatment for stroke and medical economics
本論文は,脳卒中と医療経済について概説し,当教室が行ってきた費用対効果分析の研究について紹介するものである.脳卒中は世界的に主要な死因の一つであり,高齢化が進む日本では医療費の削減が重要な課題である.脳卒中の治療には,入院治療,手術,リハビリテーション,予防などがあり,日本ではそれぞれに保険制度や診療報酬の仕組みがある.脳卒中の費用対効果に関する研究は,急性期治療,リハビリテーション,予防などの分野で多く行われており,様々な介入の有効性や経済的影響が評価されている.当教室では,北海道における脳卒中の医療サービスの費用対効果を分析し,医療資源の有効活用に寄与することを目指している.